CRTAC1 is a promising biomarker of osteoarthritis
CRTAC1 in plasma is a specific biomarker of osteoarthritis, a measure of OA risk, and a predictor of progression to joint replacements. The lack of a biomarker of osteoarthritis (OA) has hindered the development of effective therapies for this common disease.
First report from the world’s most ambitious sequencing project
Scientists at deCODE genetics a subsidiary of Amgen, together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature today.
25th anniversary of deCODE genetics
DeCODE genetics celebrated its 25th anniversary with a two day conference in Reykjavik on the 18 and 18th of May.
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
Scientists at deCODE genetics, a subsidiary of Amgen, have together with their Nordic collaborators published the largest genome-wide association study to date on rheumatoid arthritis (RA) in Annals of the Rheumatic Diseases, including over thirty thousand cases and one million controls.
UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.